United Therapeutics Says FDA Accepts sNDA For Nebulized Tyvaso Inhalation Solution To Treat IPF
Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug Administration (FDA)United
United Therapeutics asked the FDA to approve a new medicine that could be the first inhaled treatment for a serious lung disease called IPF. The FDA said yes, they'll review it, which is a good first step toward helping patients—but it's not approved yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.